Industry's PMS activities branded "unsatisfactory"
This article was originally published in RAJ Devices
Postmarket surveillance activities by medical device manufacturers in the UK remain unsatisfactory and some companies still view their clinical trial data as private property, despite this being unethical and against trade association guidance. These were some of the key points to emerge from a meeting of medtech experts hosted by the UK Medicines and Healthcare products Regulatory Agency.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.